← All Sutro Biopharma, INC filings

Sutro Biopharma, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
STRO
Sutro Biopharma, INC
10-K: Sutro Biopharma Narrows Focus, Reports $191M Loss in 2025
Sutro Biopharma reported a net loss of $191.1 million for 2025, driven by strategic restructuring and a refocused pipeline on novel ADC candidates STRO-004, STRO-006, and STRO-227.
NASDAQ
STRO
Sutro Biopharma, INC
10-K: Sutro Biopharma Reports Strategic Shift, Prioritizes Pipeline and Reduces Workforce in Annual 10-K Filing
Sutro Biopharma's 2024 10-K filing reveals a strategic shift towards prioritized pipeline programs and a significant workforce reduction to extend its cash runway.
NASDAQ
STRO
Sutro Biopharma, INC
10-K: Sutro Biopharma Details Capital Structure and Pipeline in 10-K Filing
Sutro Biopharma's 10-K filing outlines its capital structure, clinical pipeline, and strategic collaborations, highlighting its proprietary XpressCF platform and lead candidate, luvelta.